Vivos Therapeutics, Inc., a medical technology company, has filed a prospectus related to the sale of 1,737,259 shares of common stock. The shares are being offered by a selling stockholder, Armistice Capital, LLC, and are associated with common stock purchase warrants issued in private placements that occurred in January and November of 2023, and February of 2024. The company will not receive any proceeds from the sale of the common stock by the selling stockholder. However, proceeds may be received upon the exercise of the warrants for cash, which will be used for general corporate purposes and working capital. The common stock is listed on the Nasdaq under the symbol 'VVOS.' As of April 4, 2024, the last reported sale price of Vivos Therapeutics' common stock was $3.01 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The prospectus also includes a cautionary note regarding forward-looking statements and details the risks involved in investing in the common stock.

Vivos Therapeutics, Inc., a medical technology company, has filed a prospectus related to the sale of 1,737,259 shares of common stock. The shares are being offered by a selling stockholder, Armistice Capital, LLC, and are associated with common stock purchase warrants issued in private placements that occurred in January and November of 2023, and February of 2024. The company will not receive any proceeds from the sale of the common stock by the selling stockholder. However, proceeds may be received upon the exercise of the warrants for cash, which will be used for general corporate purposes and working capital. The common stock is listed on the Nasdaq under the symbol 'VVOS.' As of April 4, 2024, the last reported sale price of Vivos Therapeutics' common stock was $3.01 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The prospectus also includes a cautionary note regarding forward-looking statements and details the risks involved in investing in the common stock.